Braveheart Bio, Inc. BRVE
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17,518.52% | 82,600.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 58,722.22% | 300,880.00% | |||
| Operating Income | -58,722.22% | -300,880.00% | |||
| Income Before Tax | -3,833.86% | -14,324.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3,833.86% | -14,324.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3,833.86% | -14,324.24% | |||
| EBIT | -58,722.22% | -300,880.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -1,742.60% | -- | |||
| Normalized Basic EPS | -20,993.33% | -- | |||
| EPS Diluted | -1,695.21% | -- | |||
| Normalized Diluted EPS | -20,993.33% | -- | |||
| Average Basic Shares Outstanding | 165.07% | -- | |||
| Average Diluted Shares Outstanding | 165.07% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||